TY - JOUR
T1 - Drug Repurposing for COVID-19
T2 - A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates
AU - Rodrigues, Liliana
AU - Cunha, Renata Bento
AU - Vassilevskaia, Tatiana
AU - Viveiros, Miguel
AU - Cunha, Celso
N1 - Funding Information:
This work was supported by Funda??o para a Ci?ncia e a Tecnologia (FCT) ?Apoio Especial RESEARCH4COVID-19 project no 434?.
Funding Information:
Funding: This work was supported by Fundação para a Ciência e a Tecnologia (FCT) “Apoio Especial RESEARCH4COVID-19 project no 434”.
Publisher Copyright:
© 2022, MDPI. All rights reserved.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - In December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19) was first identified in the province of Wuhan, China. Since then, there have been over 400 million confirmed cases and 5.8 million deaths by COVID-19 reported worldwide. The urgent need for therapies against SARS-CoV-2 led researchers to use drug repurposing approaches. This strategy allows the reduction in risks, time, and costs associated with drug development. In many cases, a repurposed drug can enter directly to preclinical testing and clinical trials, thus accelerating the whole drug discovery process. In this work, we will give a general overview of the main developments in COVID-19 treatment, focusing on the contribution of the drug repurposing paradigm to find effective drugs against this disease. Finally, we will present our findings using a new drug repurposing strategy that identified 11 compounds that may be potentially effective against COVID-19. To our knowledge, seven of these drugs have never been tested against SARS-CoV-2 and are potential candidates for in vitro and in vivo studies to evaluate their effectiveness in COVID-19 treatment.
AB - In December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19) was first identified in the province of Wuhan, China. Since then, there have been over 400 million confirmed cases and 5.8 million deaths by COVID-19 reported worldwide. The urgent need for therapies against SARS-CoV-2 led researchers to use drug repurposing approaches. This strategy allows the reduction in risks, time, and costs associated with drug development. In many cases, a repurposed drug can enter directly to preclinical testing and clinical trials, thus accelerating the whole drug discovery process. In this work, we will give a general overview of the main developments in COVID-19 treatment, focusing on the contribution of the drug repurposing paradigm to find effective drugs against this disease. Finally, we will present our findings using a new drug repurposing strategy that identified 11 compounds that may be potentially effective against COVID-19. To our knowledge, seven of these drugs have never been tested against SARS-CoV-2 and are potential candidates for in vitro and in vivo studies to evaluate their effectiveness in COVID-19 treatment.
KW - Computer-aided drug discovery
KW - COVID-19
KW - Drug repurposing
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85129049485&partnerID=8YFLogxK
U2 - 10.3390/molecules27092723
DO - 10.3390/molecules27092723
M3 - Article
AN - SCOPUS:85129049485
SN - 1420-3049
VL - 27
JO - Molecules
JF - Molecules
IS - 9
M1 - 2723
ER -